SHARE NOW
Leading viral vector CDMO ViroCell Biologics has entered a strategic partnership with University College London (UCL) to accelerate research into a novel CAR-T cell therapy for relapsed pediatric acute lymphoblastic leukemia (ALL).
Focusing initially on manufacturing lentiviral and gamma-retroviral vectors, ViroCell’s scalable platform enables clients to start clinical trials, delivering value by reducing costs, time, and regulatory risks.
Professor Persis Amrolia, a pioneer in CAR-T cell therapy for pediatric ALL, leads the research at the UCL Great Ormond Street Institute of Child Health. This novel CAR-T cell therapy focuses on preserving early “stem cell memory” T cells, with dual targeting using both CD19 and CD22 CAR-T cells to prevent antigen-negative relapse.
The partnership will leverage ViroCell’s expertise in lentiviral vector manufacturing to support UCL’s Phase I CARPALL cohort 4 clinical trial, expected to initiate in Q2 2024 for children and young adults (age <18) with relapsed/refractory ALL.
Dr. Farzin Farzaneh, Chief Scientific Officer of ViroCell, stated, “We are honored to be partnering with such a prestigious research institution as UCL to bring next-generation CAR-T cells to pediatric patients with relapsed acute lymphoblastic leukemia. We at ViroCell are passionately focused on leveraging our experience in viral vector design and supply to support bringing innovative therapies like Professor Amrolia’s to patients.”
How are you enjoying this news article? Let us know your thoughts, here >>
The collaboration follows the recent approval by the UK Medicines and Healthcare products Regulatory Agency of ViroCell’s manufacturing operations at the Zayed Centre for Research, a state-of-the-art facility at Great Ormond Street Hospital. This Manufacturer’s Authorization License allows ViroCell to manufacture and globally export high-quality viral vectors for use in cell and gene therapy clinical trials.
“The depth of experience of the team, paired with their commitment to speed in manufacturing, testing, and release makes ViroCell the ideal partner for innovators looking to transition their therapy swiftly from vector design to manufacturing and, ultimately, into patients,” commented Amrolia.
Source: ViroCell Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
